FierceBiotech FierceBiotech IT FiercePharma FierceMedicalDevices
FierceBiotech Research FierceVaccines FiercePharma Manufacturing FierceDrugDelivery

Free Newsletter

About | View Sample | Privacy

Healthcare reform drives investor to IT opportunities

Free Newsletter

FierceBiotech IT updates senior biotech, pharma, and IT leaders on how IT advances are shaping clinical trials and clinical research. Get your weekly briefing on clinical trial design and management systems, adaptive trials, eClinical trials, and more. Sign up today!



Tools

Venture capital firm SV Life Sciences has positioned itself in the U.S. health IT sector, which it expects to bloom given incentives aimed at helping doctors automate. Its latest fund, the $523 million Fund V, targets companies that serve U.S. doctors, who now have a $17 billion motivation to adopt information technology, reports Xconomy.

The multimillions in incentives promised by the government are intended primarily to boost adoption of electronic medical records. So the technical terrain may appear familiar to SV, which funded e-clinical solutions provider Phase Forward more than a decade ago when the clinical trial discipline sprouted its automation wings. Phase Forward is now being purchased by Oracle.

SV doesn't restrict itself to solution providers. It helped launch IT staffing company Vitalize Consulting Solutions. The venture funds provider reasons that its own difficulty in finding solid health IT product companies to finance and develop was likely accompanied by a shortage of information technologists trained in healthcare apps.

- see the article

Related Articles:
SV Life Sciences flush with venture cash, bullish on exit deals
Researchers using healthcare records
Phase Forward brings SaaS affordability to Oracle's clinical lineup
Phase Forward boosts automation core


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotechIT Email Newsletter:

More stories about Phase Forward   electronic medical record   SV Life Sciences